JP2020528453A5 - - Google Patents

Download PDF

Info

Publication number
JP2020528453A5
JP2020528453A5 JP2020524710A JP2020524710A JP2020528453A5 JP 2020528453 A5 JP2020528453 A5 JP 2020528453A5 JP 2020524710 A JP2020524710 A JP 2020524710A JP 2020524710 A JP2020524710 A JP 2020524710A JP 2020528453 A5 JP2020528453 A5 JP 2020528453A5
Authority
JP
Japan
Prior art keywords
ibuprofen
composition according
sodium
composition
chromoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020524710A
Other languages
English (en)
Japanese (ja)
Other versions
JP7202376B2 (ja
JP2020528453A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/065727 external-priority patent/WO2019017995A1/en
Publication of JP2020528453A publication Critical patent/JP2020528453A/ja
Publication of JP2020528453A5 publication Critical patent/JP2020528453A5/ja
Application granted granted Critical
Publication of JP7202376B2 publication Critical patent/JP7202376B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020524710A 2017-07-20 2017-12-12 クロモリンナトリウムおよびイブプロフェンの粉末製剤 Active JP7202376B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762534848P 2017-07-20 2017-07-20
US62/534,848 2017-07-20
PCT/US2017/065727 WO2019017995A1 (en) 2017-07-20 2017-12-12 FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN

Publications (3)

Publication Number Publication Date
JP2020528453A JP2020528453A (ja) 2020-09-24
JP2020528453A5 true JP2020528453A5 (enExample) 2021-01-28
JP7202376B2 JP7202376B2 (ja) 2023-01-11

Family

ID=65014583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524710A Active JP7202376B2 (ja) 2017-07-20 2017-12-12 クロモリンナトリウムおよびイブプロフェンの粉末製剤

Country Status (9)

Country Link
US (3) US10561612B2 (enExample)
EP (1) EP3654946A4 (enExample)
JP (1) JP7202376B2 (enExample)
KR (1) KR20210070232A (enExample)
CN (1) CN111565711B (enExample)
AU (1) AU2017423862A1 (enExample)
CA (1) CA3070386A1 (enExample)
MX (1) MX2020000577A (enExample)
WO (1) WO2019017995A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
HK1223541A1 (zh) 2013-10-22 2017-08-04 The General Hospital Corporation 色甘酸衍生物以及成像和治疗的相关方法
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ/ミクログリア
JP2021529771A (ja) 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
IL297023A (en) 2020-04-06 2022-12-01 Massachusetts Gen Hospital Methods for treating inflammatory conditions caused by the corona virus

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686412A (en) 1965-03-25 1972-08-22 Colin Fitzmaurice Compositions containing bis-chromonyl compounds for inhibiting antigen-antibody reactions
GB1144905A (en) 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
US3957965A (en) 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
GB1257162A (enExample) 1968-02-16 1971-12-15
US4120285A (en) 1976-11-01 1978-10-17 Owens-Illinois, Inc. Modular tubular solar energy collector apparatus
DE3104294A1 (de) 1981-02-07 1982-08-19 Hoechst Ag, 6000 Frankfurt Substituierte diazaspirodecane, ihre herstellung, ihre verwendung als stabilisatoren fuer organische polymere, sowie die so stabilisierten polymeren
US4429545A (en) 1981-08-03 1984-02-07 Ocean & Atmospheric Science, Inc. Solar heating system
BE897058A (fr) 1982-06-25 1983-12-16 Sandoz Sa Utilisation d'un derive du spiro-succinimide dans le traitement de la demence du type alzheimer
US4996296A (en) 1983-07-27 1991-02-26 Yeda Research & Development Co., Ltd. Cromolyn binding protein in highly purifed form, and methods for the isolation thereof
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US4919915A (en) 1987-03-03 1990-04-24 Paul Averback Method for detecting the ability to prevent red-to-green congophilic birefringence
DE69027319T2 (de) 1989-04-28 1996-11-21 Riker Laboratories Inc., Northridge, Calif. Inhalationsvorrichtung für trockenpulver
DE4405387A1 (de) 1994-02-19 1995-08-24 Hoechst Ag Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
CA2174583A1 (en) 1995-05-05 1996-11-06 Alexander Chucholowski Sulfuric acid esters of sugar alcohols
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
AU750567B2 (en) 1997-09-29 2002-07-25 Novartis Ag Stabilized preparations for use in nebulizers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US5904937A (en) * 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6197963B1 (en) 1998-08-13 2001-03-06 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
HUP0104778A3 (en) 1998-12-24 2004-05-28 Janssen Pharmaceutica Nv Controlled release galantamine composition
JP2001151673A (ja) 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
US20020107173A1 (en) 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
ES2248283T3 (es) 2000-02-21 2006-03-16 Pharmexa A/S Nuevo procedimiento para reducir los niveles de amiloide.
US20080021085A1 (en) 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
AU5702201A (en) 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
AR035642A1 (es) 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
US20020016359A1 (en) 2000-06-29 2002-02-07 Hellberg Mark R. Compositions and methods of treating neurodegenerative diseases
US8519005B2 (en) 2000-07-27 2013-08-27 Thomas N. Thomas Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy
FR2815030A1 (fr) 2000-10-05 2002-04-12 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments
US6511960B2 (en) 2001-01-05 2003-01-28 Alphamed Pharmaceuticals Corp Cromolyn for eye and ear infections
CN100422180C (zh) 2001-04-23 2008-10-01 宾夕法尼亚州大学理事会 淀粉样斑块聚集抑制剂和诊断成像剂
US20040259952A1 (en) 2001-11-29 2004-12-23 Richat Abbas Formulations for oral administration of cromolyn sodium
US20060276455A1 (en) 2003-02-13 2006-12-07 Lindsberg Perttu J Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
WO2004093848A2 (en) 2003-04-14 2004-11-04 Vectura Ltd Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US20040223918A1 (en) 2003-05-07 2004-11-11 Chrysalis Technologies Incorporated Aerosolization of cromolyn sodium using a capillary aerosol generator
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
JP4471340B2 (ja) 2003-10-07 2010-06-02 芦森工業株式会社 バックル装置
DE10355559A1 (de) 2003-11-21 2005-06-23 Orthogen Ag Transskin
US8088935B2 (en) 2003-12-23 2012-01-03 Ironwood Pharmaceuticals, Inc. Compounds and methods for the treatment of asthma
WO2005077394A1 (en) 2004-02-11 2005-08-25 Ramot At Tel-Aviv University Ltd Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid
WO2006001877A2 (en) 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
EP2708225B1 (en) 2004-04-23 2018-12-26 CyDex Pharmaceuticals, Inc. DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin
CA2577268A1 (en) 2004-08-30 2006-03-09 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
KR20070122497A (ko) 2005-04-22 2007-12-31 제넨테크, 인크. Cd20 항체로 치매 또는 알츠하이머병을 치료하는 방법
CA2609980C (en) 2005-05-27 2015-10-13 Queen's University At Kingston Treatment of protein folding disorders
CA2631493A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US8263645B2 (en) 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
AR059356A1 (es) 2006-02-14 2008-03-26 Astrazeneca Ab Nuevos radioligandos
US7700618B2 (en) 2006-03-06 2010-04-20 Pfizer Inc Sulfonyl benzimidazole derivatives
EP1996175A4 (en) 2006-03-09 2009-06-10 Waratah Pharmaceuticals Inc CYCLOHEXAN POLYALKOHOL FORMULATION FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
US7700616B2 (en) 2006-05-08 2010-04-20 Molecular Neuroimaging, Llc. Compounds and amyloid probes thereof for therapeutic and imaging uses
US8445437B2 (en) 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
US20100173960A1 (en) 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
EP2091566A4 (en) 2006-11-24 2011-07-06 Waratah Pharmaceuticals Inc COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES
US20080292625A1 (en) 2007-04-18 2008-11-27 Sally Schroeter Prevention and treatment of cerebral amyloid angiopathy
WO2008128981A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors
US7858803B2 (en) 2007-04-27 2010-12-28 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
CA2693771A1 (en) 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
GB0714134D0 (en) 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5501339B2 (ja) 2008-03-21 2014-05-21 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物
BRPI0911874A2 (pt) 2008-04-29 2018-05-22 Pharnext composições combinadas para o tratamento da doença de alzheimer e doenças relacionadas com zonisamida e acamprosato
JP5816883B2 (ja) 2009-01-22 2015-11-18 ラクオリア創薬株式会社 Cb2受容体作動活性を有するn−置換飽和ヘテロ環スルホン化合物
US8381454B1 (en) 2009-01-23 2013-02-26 Markus R. Robinson Segmented, elongated, expandable, 4-season, double-walled, low-cost, rigid extruded plastic panel structures
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US8617517B2 (en) 2009-01-29 2013-12-31 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
TW201613969A (en) 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
US8129404B2 (en) 2009-03-11 2012-03-06 Plexxikon Inc. Compounds and uses thereof
US8377947B2 (en) 2009-03-16 2013-02-19 Chien-Hung Chen Treating alzheimer's disease and osteoporosis and reducing aging
PL2248517T3 (pl) 2009-05-08 2014-08-29 Pari Pharma Gmbh Stężone formulacje farmaceutyczne stabilizujące komórki tuczne
AU2010281524A1 (en) 2009-08-06 2012-02-23 Neuraltus Pharmaceuticals, Inc. Treatment of macrophage-related disorders
WO2011032164A2 (en) 2009-09-14 2011-03-17 Kmetovicz Ronald E Solar heat pipe heat exchanger
MX2012003083A (es) 2009-09-24 2012-04-30 Wista Lab Ltd Clorhidratos de metiltioninio (azul de metileno) cristalinos.
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US20110262442A1 (en) 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
MX337603B (es) * 2009-11-30 2016-03-10 Adare Pharmaceuticals Inc Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion.
US8455755B2 (en) 2009-12-07 2013-06-04 Electrotherm Concentrated photovoltaic and thermal solar energy collector
US20110256064A1 (en) 2010-04-16 2011-10-20 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
WO2011136754A1 (en) 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
TR201901644T4 (tr) 2010-09-30 2019-02-21 Chiesi Farm Spa İnhalasyon için kuru toz formülasyonlarında magnesyum stearat. kullanımı.
US20120121656A1 (en) 2010-11-15 2012-05-17 Revalesio Corporation Methods and compositions for protecting against neurotoxicity of a neurotoxic agent, and improving motor coordination associated with a neurodegenerative condition or disease
CA2827027C (en) 2011-02-11 2019-06-04 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
KR20150011807A (ko) 2012-05-25 2015-02-02 질리어, 인크. 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
CA2913235C (en) 2013-05-23 2021-07-13 Aztherapies, Inc. Methods for delivering cromolyn
HK1223541A1 (zh) 2013-10-22 2017-08-04 The General Hospital Corporation 色甘酸衍生物以及成像和治疗的相关方法
WO2015120392A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
DK3104853T3 (da) 2014-02-10 2019-12-09 Respivant Sciences Gmbh Behandling med mastcellestabilisatorer til systemiske forstyrrelser
US11723864B2 (en) * 2015-05-29 2023-08-15 The Texas A&M University System Antimicrobial and anti-inflammatory compositions
KR20180081807A (ko) 2015-11-19 2018-07-17 아즈테라피즈 인코포레이티드 알츠하이머 질환 및 관련 장애의 치료 방법
JP2018538273A (ja) 2015-11-23 2018-12-27 エーゼットセラピーズ, インコーポレイテッド 虚血性脳卒中を処置するための組成物および方法
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ/ミクログリア

Similar Documents

Publication Publication Date Title
JP2020528453A5 (enExample)
JP2010508929A5 (enExample)
JP2009512663A5 (enExample)
WO2005025535A3 (en) Methods for preparing pharmaceutical compositions
JP2015157851A5 (enExample)
RU2014140539A (ru) Агрегированные частицы
CN102665764A (zh) 可用作可再压实药物赋形剂的微晶纤维素和碳酸钙组合物
Tajber et al. Spray drying of budesonide, formoterol fumarate and their composites—I. Physicochemical characterisation
JP2004002290A (ja) 直接圧縮用β−マンニトールの製造方法
JP6883039B2 (ja) 呼吸域ザフィルルカスト粒子の調製方法
CN110465389B (zh) 一种非机械接触式珍珠粒粉碎装置
EP2806856A1 (en) Drug/carrier inclusion composites prepared by a mechanochemical activation process using high-energy fluid-jet mills
CN112451509B (zh) 一种川丁特罗吸入粉雾剂及其制备方法
JP4092568B2 (ja) 微粉末ケイ素又はケイ素化合物の製造方法
JP2002503703A5 (enExample)
JP4024566B2 (ja) 気流式粉砕・分級機
Bya et al. Formulation of a dry powder for inhalation combining ciclesonide and indacaterol maleate using spray drying
CN102114544A (zh) 一种制备粒径分布均匀且球形度和分散性好的钨粉的方法
Vatsaraj et al. Optimization of the operating conditions of a lab scale Aljet mill using lactose and sucrose: a technical note
HRP20120106T1 (hr) Farmaceutski pripravci entakapona koji su mikronizirani zajedno sa šećernim alkoholima
CN108743542B (zh) 药物微粉、制备方法及其应用
JP2008000657A (ja) 超微小粒粉砕装置
JP2000297303A (ja) 導電性粉末の粉砕方法およびこれを用いた導電性塗料
CN1824012A (zh) 十全大补快速分散固体制剂及其制备方法
CN208066497U (zh) 一种超细碳化硅气流粉碎室